These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6733813)

  • 1. Evaluation of cyclodextrin polymer as an additive for furosemide tablet.
    Fenyvesi E; Takayama K; Szejtli J; Nagai T
    Chem Pharm Bull (Tokyo); 1984 Feb; 32(2):670-7. PubMed ID: 6733813
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclodextrin polymer, a new tablet disintegrating agent.
    Fenyvest E; Antal B; Zsadon B; Szejtli J
    Pharmazie; 1984 Jul; 39(7):473-5. PubMed ID: 6494226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Properties of cyclodextrin polymer as a tabletting aid.
    Fenyvesi E; Shirakura O; Szejtli J; Nagai T
    Chem Pharm Bull (Tokyo); 1984 Feb; 32(2):665-9. PubMed ID: 6733812
    [No Abstract]   [Full Text] [Related]  

  • 4. Production and investigating of tablets containing furosemide and beta-cyclodextrin.
    Kata M; Haragh L; Pintye-Hódi K
    Acta Pharm Hung; 1990 Jan; 60(1):40-5. PubMed ID: 2327256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on cyclodextrin polymer. Part 1: The effect of CDP on indomethacin tablet formulation.
    Tarimci N; Celebi N
    Pharmazie; 1988 May; 43(5):323-5. PubMed ID: 3174808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The investigation of cyclodextrin polymer as a new disintegrant for direct compressed tablets.
    Sekulović D; Zajić L
    Pharmazie; 1987 Aug; 42(8):556. PubMed ID: 3432343
    [No Abstract]   [Full Text] [Related]  

  • 7. [Molecular cavity filling and tabletting with beta-cyclodextrin].
    Hüttenrauch R; Fricke S
    Pharmazie; 1985 May; 40(5):361-2. PubMed ID: 4034643
    [No Abstract]   [Full Text] [Related]  

  • 8. Preparation and investigation of hydrochlorothiazide products containing beta-cyclodextrin.
    Kata M; Lukács M
    Pharmazie; 1984 Dec; 39(12):857-8. PubMed ID: 6531397
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of hot-melt extrusion and injection molding for continuous manufacturing of immediate-release tablets.
    Melocchi A; Loreti G; Del Curto MD; Maroni A; Gazzaniga A; Zema L
    J Pharm Sci; 2015 Jun; 104(6):1971-1980. PubMed ID: 25761921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of beta-cyclodextrin during direct pressing of tablets].
    Szabóné RP; Pintyéné HK; Kun L; Miseta M; Selmeczi B
    Acta Pharm Hung; 1989 May; 59(3):99-107. PubMed ID: 2763849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
    Lin SY; Lin KH; Li MJ
    J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of a phenytoin beta-cyclodextrin complex and evaluation of a suspension and a tablet dosage form prepared from the complex.
    Hegde RP; Rhodes CT
    Pharm Acta Helv; 1985; 60(2):53-7. PubMed ID: 3991746
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhancement of solubility of furosemide with beta-cyclodextrin.
    Kata M; Antal A
    Pharmazie; 1984 Dec; 39(12):856-7. PubMed ID: 6531396
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between crystallinity of beta-cyclodextrin and tablet characteristics.
    Nakai Y; Yamamoto K; Terada K; Kajiyama A
    Chem Pharm Bull (Tokyo); 1985 Nov; 33(11):5110-2. PubMed ID: 3830437
    [No Abstract]   [Full Text] [Related]  

  • 16. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients.
    Pitha J; Pitha J
    J Pharm Sci; 1985 Sep; 74(9):987-90. PubMed ID: 4067854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of cyclodextrins in parenteral formulations.
    Brewster ME; Simpkins JW; Hora MS; Stern WC; Bodor N
    J Parenter Sci Technol; 1989; 43(5):231-40. PubMed ID: 2681643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some factors affecting properties and dissolution behavior of tableted furosemide microspheres.
    Akbuğa J
    Pharmazie; 1992 Feb; 47(2):128-31. PubMed ID: 1635921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Beta-cyclodextrin as an auxiliary substance in tabletting (preliminary communication)].
    Krajnyák J; Rácz I; Dávid A; Szejtli J
    Acta Pharm Hung; 1984 Mar; 54(2):90-1. PubMed ID: 6730980
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmaceutical applications of cyclodextrin complexations (author's transl)].
    Uekama K
    Yakugaku Zasshi; 1981 Oct; 101(10):857-73. PubMed ID: 7040632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.